Related Experiment Video

Updated: Apr 12, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.5K

Cardamonin Inhibits Metastasis of Lewis Lung Carcinoma Cells by Decreasing mTOR Activity

Pei-Guang Niu1, Yu-Xuan Zhang1, Dao-Hua Shi1

  • 1Department of Pharmacy, Fujian Provincial Maternal and Child Health Hospital, Fuzhou, Fujian, China.

Plos One
|May 22, 2015
PubMed

Insights

Cardamonin, a natural compound, effectively inhibits cancer cell invasion and metastasis by targeting the mammalian target of rapamycin (mTOR) pathway. This study demonstrates cardamonin

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Mammalian target of rapamycin (mTOR) pathway is crucial for cancer cell motility and invasion.
  • Cardamonin, a chalcone, possesses anti-tumor properties linked to mTOR inhibition.
  • Lewis lung carcinoma (LLC) cells are a model for highly metastatic cancer.

Purpose of the Study:

  • To investigate the anti-metastatic effects of cardamonin on LLC cells.
  • To elucidate the molecular mechanisms underlying cardamonin's anti-metastatic action.
  • To evaluate the in vivo efficacy of cardamonin against LLC metastasis.

Main Methods:

  • Cell proliferation, invasion, and migration assays (MTT, Transwell, Wound Healing).
  • Western blotting to assess mTOR pathway and adhesion-related protein expression/activation.
  • In vivo mouse model (C57BL/6) to study metastasis and tumor growth.

Main Results:

  • Cardamonin significantly inhibited LLC cell proliferation, invasion, and migration.
  • Cardamonin treatment led to decreased Snail expression and increased E-cadherin expression.
  • Cardamonin suppressed mTOR activation and its downstream target S6K1.
  • In vivo, cardamonin reduced tumor growth and lung metastasis in mice.

Conclusions:

  • Cardamonin exhibits anti-metastatic effects on Lewis lung carcinoma cells by inhibiting the mTOR pathway.
  • The anti-metastatic mechanism involves down-regulation of Snail and up-regulation of E-cadherin.
  • Cardamonin shows therapeutic potential for inhibiting cancer metastasis.

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.9K
CAM-Delam Assay to Score Metastatic Properties by Quantifying Delamination and Invasion Capacity of Cancer Cells12:14

CAM-Delam Assay to Score Metastatic Properties by Quantifying Delamination and Invasion Capacity of Cancer Cells

Published on: June 2, 2022

3.2K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.7K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K